Actuate Therapeutics receives Nasdaq notice of MVLS deficiency, has 180 days to cure
Actuate Therapeutics received a notice from Nasdaq on July 15, 2026, that its Market Value of Listed Securities (MVLS) fell below the $50 million minimum…
$50M180 calendar days